Document Detail

Mitoxantrone (M) and vinblastine (V) in the treatment of advanced breast cancer.
MedLine Citation:
PMID:  2184548     Owner:  NLM     Status:  MEDLINE    
Twenty-four patients with metastatic breast cancer, all but 1 pretreated with one or more chemotherapeutic regimens, were entered in a pilot study to assess toxicity and efficacy of the combination mitoxantrone and vinblastine. Dominant sites of metastases were viscera in 9 patients, bone in 10 and soft tissues in 5. All patients received mitoxantrone 10 mg/m2 i.v. on day 1 and vinblastine 1.7 mg/m2 by 4 hour infusion on days 3, 4 and 5, every 3-4 weeks. Objective responses (1 CR, 7 PR) were observed in 8 (38%) of the 21 evaluable patients. Median duration of response was 10.5 months. Of 12 patients pretreated with an anthracycline containing regimen, 4 responded (1 CR and 3 PR). Major toxicity was myelosuppression, grade 4 in 2 cases and grade 3 in 2 others. No evident alopecia was observed and only 1 case of grade 1 cardiac toxicity. In conclusion, mitoxantrone followed by vinblastine is an effective regimen in metastatic breast cancer also in pretreated patients, and previous anthracycline administration does not seem to reduce the percentage of response. Moreover, toxicity is generally mild.
G Cruciani; A Tienghi; G Fiorentini; G Rosti; D Turci; V Salerno; M Leoni; M Marangolo
Related Documents :
21590228 - Dukes' a tumor.
21679408 - Intensity modulated radiotherapy for elderly bladder cancer patients.
1327568 - Phase ii study of edatrexate in stage iii and iv non-small-cell lung cancer.
2344968 - Teniposide in recurrent or advanced cervical carcinoma: a phase ii trial in patients no...
21640518 - Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (st...
15110448 - Escalated hyperfractionated accelerated radiation therapy for locally advanced non-smal...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Tumori     Volume:  76     ISSN:  0300-8916     ISO Abbreviation:  Tumori     Publication Date:  1990 Apr 
Date Detail:
Created Date:  1990-05-30     Completed Date:  1990-05-30     Revised Date:  2008-12-12    
Medline Journal Info:
Nlm Unique ID:  0111356     Medline TA:  Tumori     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  196-8     Citation Subset:  IM    
Divisione di Oncologia Medica, Ospedale S. Maria delle Croci, Ravenna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Clinical Trials as Topic
Doxorubicin / therapeutic use
Drug Administration Schedule
Epirubicin / therapeutic use
Infusions, Intravenous
Middle Aged
Mitoxantrone / administration & dosage,  adverse effects
Vinblastine / administration & dosage,  adverse effects
Reg. No./Substance:
23214-92-8/Doxorubicin; 56420-45-2/Epirubicin; 65271-80-9/Mitoxantrone; 865-21-4/Vinblastine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  5-Fluorouracil carcinogenesis in BALB/c mice.
Next Document:  Evaluating radiation in combination with hyperthermia trials: the importance of clinical and technic...